![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The collaboration aims to inform the delivery model design of investigational COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD).
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Compass Pathways
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 16, 2024